Cargando…
Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
BACKGROUND: The safety of immune checkpoint inhibitors (ICIs) in patients with hepatitis C virus (HCV) infection has not been studied in many cancers, as these patients were excluded from most ICI trials. This poses a degree of uncertainty when a patient with HCV is being considered for ICIs in the...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100564/ https://www.ncbi.nlm.nih.gov/pubmed/33655663 http://dx.doi.org/10.1002/onco.13739 |